CLOs on the Move

Decibel Therapeutics

www.decibeltx.com

 
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel`s pipeline, including its lead gene therapy program, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.decibeltx.com
  • 1325 Boylston Street Suite 500
    Boston, MA USA 02215
  • Phone: 617.370.8701

Executives

Name Title Contact Details
Cynthia Hu
Chief Legal Officer and Corporate Secretary Profile
George Xixis
Vice President Legal Affairs and Intellectual Property Profile

Similar Companies

William Gallagher Associates

William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Perimeter Resources

Perimeter Resources is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

IVFCRYO

Ensuring safe and secure management of reproductive specimens world wide. Tank failures happen. Specimens don’t have to be lost because of that. We can help.

Rain Therapeutics

Rain Therapeutics is a clinical-stage precision oncology company. Our uncompromised dream is to develop and implement the best precision oncology therapies for patients suffering from cancer. We are rooted in this purpose — extending the quality and length of life for cancer patients where we may be their best hope.

Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.